|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
New targeted therapies for hematological malignancy include chimeric antigen receptor T cells (CAR T cells), Bi-specific T-cell Engager (BiTE) blinatumomab, and the antibody-drug conjugate (ADC) of calicheamicin inotuzumab ozogamicin for acute lymphoblasic leukemia (ALL) and lymphoma; the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib and phosphatidylinositol 3-kinase (PI3Kδ) inhibitor idelalisib for lymphoma and graft-versus-host disease (GVHD); FMS-like tyrosine kinase 3 (FLT3) inhibitors, such as midostaurin, sorafenib and gilteritinib for acute myeloid leukemia (AML); and the BCL-2 inhibitor venetoclax for a range of hematological malignancies including lymphoma and leukemia.
|
31688198 |
2019 |
|
Lymphoma
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Radiotherapy is a rational candidate for combining with BCL-2 inhibition, as DNA damage caused by radiotherapy increases the activity of pro-apoptotic BCL-2 pathway proteins, and lymphomas are exquisitely sensitive to radiation.
|
28566329 |
2017 |
|
Lymphoma
|
0.500 |
AlteredExpression
|
group |
BEFREE |
None of the lymphomas expressed Bcl-2 or p53 protein, and bcl-2 gene rearrangements were not found in the three lymphomas studied.
|
10193956 |
1999 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
On re-examination, the lymph node 8 years prior was verified as follicular, predominantly small, cleaved cell lymphoma with bcl2-positive follicles.
|
10782887 |
2000 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Conversely, bcl-2 gene and Epstein-Barr virus do not appear to be involved in the pathogenesis of these peculiar lymphomas.
|
1713514 |
1991 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
We used a battery of antibodies directed against the following: cytokeratins (CKs) 5, 10, 17, and 19, actin, cell-adhesion proteins (desmoplakins, desmogleins), markers of terminal epidermal differentiation (filaggrin, involucrin and loricrin), markers of proliferation (PCNA, MIB, K6,16), a marker of endocytosis (clathrin) and markers of cell growth, (transforming growth factor [TGF-alpha]) and B-cell leukemia/lymphoma-2 [bcl-2].
|
8850247 |
1995 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Many of the cases in this DLBCL/BL category contain a translocation of MYC as well as BCL2, so-called "double-hit lymphomas" which have a very aggressive clinical behavior.
|
22035756 |
2011 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
When compared to two large published DTHL cohorts, t(3;8)(q27;q24) lymphomas less often expressed BCL2 (P < .01), had a greater likelihood of extranodal involvement (P < .01), and more frequently appeared triple-hit by FISH analysis (P < .01).
|
29902576 |
2018 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
As bcl-2 proteins, cyclin dependent kinases (CDK) and phosphoinositol-3- kinase (PI3K) also influence mitochondrial physiology and metabolism with clear relevance to the pathogenesis of lymphoma, we investigated the potentiating effects of metformin when combined with novel agents Venetoclax (bcl-2 inhibitor), BAY-1143572 (CDK9 inhibitor) and Idelalisib (p110δ- PI3K inhibitor).
|
29765528 |
2018 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
BI79D10 also effectively induces apoptosis of the RS11846 human lymphoma cell line in a dose-dependent manner and shows little cytotoxicity against bax-/-bak-/- mouse embryonic fibroblast cells, in which antiapoptotic Bcl-2 family proteins lack a cytoprotective phenotype, implying that BI79D10 has little off-target effects.
|
19372563 |
2009 |
|
Lymphoma
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Moreover, CCl4-induced apoptosis in the mouse liver was inhibited by hSAP, as measured by terminal-deoxynucleotidyl transferase mediated nick-end labeling (TUNEL) assay and cleaved caspase-3 expression. hSAP significantly restored the expression of B cell lymphoma/leukemia (Bcl)-2 and suppressed the expression of Bcl-2-associated X protein (Bax) in vivo.
|
28627620 |
2017 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Our aims are to document if bcl-2 gene rearrangement exists in Jordanian FL and DLBCL, and if present to determine whether its frequency among these lymphomas is different from the West and therefore may be responsible for some of the epidemiological differences seen between Jordan and the West.
|
15770300 |
2005 |
|
Lymphoma
|
0.500 |
AlteredExpression
|
group |
BEFREE |
In both human lymphoma and carcinoma, BCL2 expression contributes to the neoplastic development by preventing normal turnover due to programmed cell death.
|
9029764 |
1997 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
An antisense oligodeoxynucleotide (ODN) complementary to the first six codons of the Bcl-2 mRNA, G3139 (oblimersen sodium; Genasense), has been shown to downregulate Bcl-2 and produce responses in a variety of malignancies including drug-resistant lymphoma.
|
12529680 |
2003 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Moreover, genetic ablation of Kmt2d in mice overexpressing Bcl2 increases the incidence of GC-derived lymphomas resembling human tumors.
|
26366712 |
2015 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Here, we review the currently available data about the incidence, biological effects, and possible clinical importance of somatic mutations within the translocated bcl-2 genes of human lymphomas and leukemias.
|
8220113 |
1993 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Bcl-2 overexpressing DoHH2 lymphoma and HeLa-cells were transfected with ODN's using a polycationic liposome preparation.
|
12136520 |
2002 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Quantitation of bcl-2 oncogene in cultured lymphoma/leukemia cell lines and in primary leukemia B-cells by a highly sensitive RT-PCR method.
|
8647513 |
1996 |
|
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Lymphoma viability remained unaffected by the genetic deletion or pharmacological inhibition of all alternative BCL-2 family members.
|
27055871 |
2016 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
To assess the presence of bcl-2/JH rearrangements in bone marrow and peripheral blood lymphocytes from patients affected by diseases other than malignant lymphomas.
|
10193514 |
1998 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Using primers specific for chromosomes 14 and 18, translocation of the proto-oncogene bcl-2 was detected by polymerase chain reaction (PCR) in all five lymphomas positive by Southern blot analysis.
|
1940802 |
1991 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
In the present study, we investigated Bcl-2's mechanism of action by determining the effect of Bcl-2 on intracellular Ca2+ fluxes in the WEHI7.2 mouse lymphoma cell line, which does not express Bcl-2, and its stable transfectant, W.Hb12, which expresses a high level of Bcl-2.
|
8842514 |
1996 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Lymphoma grown in laboratory animals responds to BCL-2 antisense oligonucleotides with few toxic effects.
|
9113013 |
1997 |
|
Lymphoma
|
0.500 |
AlteredExpression
|
group |
BEFREE |
It is highly debated whether cases of follicular lymphoma without BCL-2 gene rearrangement and expression represent a separate lymphoma entity with distinct biological characteristics, different from the BCL-2-positive cases.
|
18945749 |
2008 |
|
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Furthermore, ectopic expression of Bcl-X(L) (but not Bcl-2) in two B-lymphoma cell lines decreased their sensitivity to parthenolide-induced apoptosis.
|
22155272 |
2012 |